Indication
Solid tumors
-
About ADC
- ADC is a next-generation anti-cancer drug called "Magic Bullet" with low side effects and high efficacy
- ADC overcomes the limitations of current treatments and the market size is expected to continue to grow
- By conjugating suitable anti-cancer drugs to antibodies, ADCs can be applied to novel treatment options for various solid cancers
-
Mode of Action
- ED2 is specifically expressed on the cell surface of cancer-associated fibroblasts (CAFs) in the tumor microenvironment of colon cancer, and it promotes cancer cell proliferation and invasion.
- ED2 antibody-drug conjugates bind to ED2, enter into the cell, and then cytotoxic substances are released by specific enzymatic cleavage reaction, ultimately leading to the destruction of cancer-associated fibroblasts or cancer cells.
-
Core Competitiveness
- Target feasibility confirmed in animal models and human specimen
- Antibody candidates ready to be applicable for Drug conjugation are in hands
- In vitro and in vivo assay systems are established
Development Status
Efficacy study with ED2 ADC candidates